Log in or Sign up for Free to view tailored content for your specialty!
Biologics/Immunotherapy News
Top news of January: Dupilumab for eosinophilic esophagitis, cell phone allergy, more
Healio compiled the most-read news in allergy, asthma and immunology posted in January.
Most dupilumab use for asthma, CRSwNP categorized as persistent
Researchers characterized the use of dupilumab among a cohort of patients with asthma, chronic rhinosinusitis with nasal polyps or both as persistent in a study published in Annals of Allergy, Asthma & Immunology.
Log in or Sign up for Free to view tailored content for your specialty!
Success limited in oral immunotherapy for adults with food allergies
Adults experienced limited success with oral immunotherapy for food allergies, with about half of a cohort halting treatment within 2 years, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Dupilumab safe for long-term use to treat moderate to severe asthma
Dupilumab appeared safe for long-term use among patients with moderate to severe asthma or oral corticosteroid-dependent severe asthma, according to data from the TRAVERSE continuation study.
Asthma exacerbation reductions similar across seasons with dupilumab
Patients with type 2 inflammation experienced reductions in asthma exacerbations with dupilumab, with no differences between seasons, according to a study published in Annals of Allergy, Asthma & Immunology.
Peanut immunotherapy uses synthetic peptides for safety, durability
An immunotherapy comprising seven synthetic peptides may provide a safe and durable alternative to immunotherapies based on whole peanuts, according to a study published in Allergy.
Early sublingual immunotherapy for allergic rhinitis reduces risks for allergic asthma
Children who begin sublingual immunotherapy for allergic rhinitis at age 5 years have less risk for developing allergic asthma than children who begin this treatment later, according to a study published in Allergy.
Patients on benralizumab for asthma maintain control with reduced corticosteroid doses
Patients who take benralizumab for severe eosinophilic asthma can reduce their inhaled corticosteroid doses while maintaining asthma control for up to 48 weeks, according to a study published in The Lancet.
Better application of biologics may lead to asthma remission, prevention
ANAHEIM, Calif. — The use of biologics for asthma will grow as physicians better define who will respond to specific treatments, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Top asthma stories of 2023
This year’s asthma research covered a broad variety of topics, such as the effect of the family dog’s fur on long-term outcomes, asthma care in prison, fast food restaurants and the Canadian wildfires.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read